When breast cancer patients 65 or older were asked, they reported being more satisfied with the cosmetic outcomes of less radiation, in the long term. However, this should be balanced with a slightly higher recurrence risk.
Adding pertuzumab to a standard regimen for hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer improved progression-free survival. These were the recently announced results of a clinical trial.
Women diagnosed with stage 1 or 2 breast cancer used a scalp-cooling system while undergoing chemotherapy, in a clinical trial. The results show that it helped them prevent hair loss.
Adding veliparib to carboplatin and paclitaxel chemotherapy improved the overall response rate among patients with locally recurrent or metastatic breast cancer with BRCA1 or BRCA2 mutations. This was achieved without increasing side-effects.
Adding everolimus to fulvestrant more than doubled progression-free survival for women with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy.
Progression-free survival doubled in some patients with metastatic breast cancer treated with everolimus plus fulvestrant, compared with fulvestrant alone. These are results from a randomized trial.
Many breast cancer patients will consider breast reconstruction after mastectomy. Radiation therapy can alter the tissue around the breast, reportedly increasing women’s concerns.
A clinical trial focused on patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer. Combining buparlisib with fulvestrant improved outcomes, but researchers feel more studies are needed.
The U.S. FDA has approved bevacizumab for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The approval indicates combination with other agents.
New research shows some patients with chronic myeloid leukemia can stop their treatment once in remission. What's more, they may even benefit from doing so.
Emerging research seems to indicate that women who had breast cancer and maintain a normal weight have lower risk of the cancer coming back.
Adding palbociclib to letrozole for the treatment of estrogen receptor positive (ER+), HER2-negative (HER2-) advanced breast cancer showed substantial benefit.
Women who have a history of depression may have worse survival outcomes, compared to patients without past mental health challenges.
Palbociclib is now approved in Europe for the treatment of women with hormone receptor-positive, HER2-negative (HR+/HER2-), locally advanced or metastatic breast cancer.
Breast cancer patients with high vitamin D levels in the blood may have less dangerous tumors and better outcomes. This is according to research within an ongoing study.
Older women enjoy the same benefits from breast reconstruction following mastectomy for breast cancer as younger women. This is according to a recently published comprehensive study.
Pembrolizumab has been approved by the FDA, for the first-line treatment of patients with metastatic non-small cell lung cancer.
Precision medicine in cancer care can help patients and doctors decide when chemotherapy is needed. For that reason, risk of recurrence and stage disease should be assessed.
High-intensity exercise training before surgery appears to improve aerobic performance in non-small cell lung cancer patients but it does not reduce the complications after tumor resection.
The U.S. Food and Drug Administration granted approval to olaratumab with doxorubicin combination treatment for patients with certain soft tissue sarcoma. Soft tissue sarcoma can be developed in the muscles, fat, nerves, etc.